类风湿关节炎中体重指数对心血管风险的影响随抗瓜氨酸化蛋白抗体状态和生物制剂使用而异
研究评估3982例国际观察队列类风湿关节炎患者,记录192例主要不良心血管事件和319例总事件。多变量Cox模型显示体重指数、ACPA和生物制剂间存在三重交互作用;ACPA阴性生物制剂使用者中体重指数与主要不良心血管事件呈反向关联(HR 0.38),ACPA阳性患者中体重指数与主要不良心血管事件独立于生物制剂使用相关(HR 1.04)。
要点
- ACPA阴性生物制剂使用者中,体重指数与主要不良心血管事件呈反向关联(HR 0.38,95%CI 0.25至0.57),非使用者中无此关联(交互P<0.001)。
- ACPA阳性患者中,体重指数与主要不良心血管事件相关(HR 1.04,95%CI 1.01至1.07),独立于生物制剂使用。
- 体重指数、ACPA和生物制剂对主要不良心血管事件存在三重交互作用(交互P<0.001),对总事件亦存在(交互P=0.028)。
核心结论
- 体重指数仅在有生物制剂使用的ACPA阴性患者中与心血管风险呈反向关联,而在ACPA阳性患者中与心血管风险相关且独立于生物制剂使用。
研究设计与样本
- 国际观察性队列研究,纳入3982例类风湿关节炎患者,采用按中心风险分层的多变量Cox模型评估体重指数、ACPA、生物制剂及其两重和三重交互作用对结局的影响。
主要发现
- 共记录192例主要不良心血管事件和319例总事件。
- 未观察到体重指数、ACPA或生物制剂的主效应。
- 体重指数、ACPA和生物制剂对主要不良心血管事件存在三重交互作用(交互P<0.001),对总事件亦存在(交互P=0.028)。
- ACPA阴性生物制剂使用者中,体重指数与主要不良心血管事件呈反向关联(HR 0.38,95%CI 0.25至0.57),与总事件亦呈反向关联(HR 0.67,95%CI 0.49至0.92);非使用者中无此关联(交互P<0.001和0.012)。
- ACPA阳性患者中,体重指数与主要不良心血管事件相关(HR 1.04,95%CI 1.01至1.07),与总事件相关(HR 1.03,95%CI 1.00至1.06),独立于生物制剂使用。
关键数值与推荐
- 主要不良心血管事件定义包括心肌梗死、卒中或心血管死亡;总事件包括主要不良心血管事件、心绞痛、血运重建、短暂性脑缺血发作、外周动脉疾病和心力衰竭。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The impact of body mass index (BMI) on cardiovascular risk in rheumatoid arthritis (RA) is unclear. RA characteristics may influence the association between BMI and risk. Disease activity, which predicts cardiovascular risk, is associated with obesity only among anticitrullinated antibody (ACPA)-positive patients. Biologics alter body composition and mitigate cardiovascular risk in RA. We explored the association of BMI with cardiovascular risk and whether this varied across ACPA status and biologic use. METHODS: We evaluated 3982 patients from an international observational cohort. Outcomes included (a) first major adverse cardiovascular event (MACE) encompassing myocardial infarction, stroke or cardiovascular death; and (b) all events comprising MACE, angina, revascularisation, transient ischaemic attack, peripheral arterial disease and heart failure. Multivariable Cox models stratified by centre risk evaluated the impact of BMI, ACPA, biologics and their two- and three-way interactions on outcomes. RESULTS: We recorded 192 MACE and 319 total events. No main effects of BMI, ACPA or biologics were observed. A three-way interaction between them on MACE (p-interaction<0.001) and all events (p-interaction=0.028) was noted. Among ACPA negative patients, BMI was inversely associated with MACE (HR 0.38 (95% CI 0.25 to 0.57)) and all events (HR 0.67 (0.49 to 0.92)) in biologic users but not non-users (p-for-interaction <0.001 and 0.012). Among ACPA-positive patients, BMI was associated with MACE (HR 1.04 [1.01-1.07]) and all events (HR 1.03 (1.00 to 1.06)) independently of biologic use. CONCLUSIONS: BMI is inversely associated with cardiovascular risk only among ACPA-negative biologic users. In contrast, BMI is associated with cardiovascular risk in ACPA-positive patients independently of biologic use.
引用
- Karpouzas GA, Gonzalez-Gay MA, Corrales A, et al. Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use. RMD Open. 2025. PMID: 40187772. doi:10.1136/rmdopen-2025-005464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。